Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays

BioTechniques

Volumn 45, Issue 4, 2008, Pages 1-6

  Lueking, Angelika ^a   Beator, Jens ^a   Patz, Elisabeth ^b   Müllner, Stefan ^a   Mehes, Gabor ^c   Amersdorfer, Peter ^b  

^a PROTAGEN AG   (Germany)

^b ORIDIS Biomed GmbH   (Austria)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; CLASSIFICATION; EPITHELIUM; HUMAN; IMMUNOLOGY; METHODOLOGY; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; EPITHELIUM; HUMANS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 71049184948     PISSN: 07366205     EISSN: 19409818     Source Type: Journal    
DOI: 10.2144/000112898     Document Type: Article

References (15)

1. Bradbury, A.R. and J.D. Marks. 2004. Antibodies from phage antibody libraries. J. Immunol. Methods 290:29-49.
2. Boder, E.T. and K.D. Wittrup. 1997. Yeast surface display for screening combinatorial polypeptide libraries. title typejournalNat. Biotechnol/title. 15:553-558.
3. Jakobovits, A., R.G. Amado, X. Yang, L. Roskos, and G. Schwab. 2007. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 25:1134-1143.
4. Lonberg, N. 2005. Human antibodies from transgenic animals. Nat. Biotechnol. 23:1117-1125.
5. Lueking, A., M. Horn, H. Eickhoff, K. Buessow, H. Lehrach, and G. Walter. 1999. Protein microarrays for gene expression and antibody screening. Anal. Biochem. 270 103-111.
6. Kallioniemi, O.-P., U. Wagner, J. Kononen, and G. Sauter. 2001. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10:657-662.
7. Simon, R. and G. Sauter. 2002. Tissue microarrays for miniaturized high-through-put molecular profiling of tumors. Exp. Hematol. 30:1365-1372.
8. Herrlich, P. 1993. CD44 splice variants: metastases meet lymphocytes. Immunol. Today 14:395-399.
9. Pals, S.T., G. Koopman, K.H. Heider, A. Griffioen, G.R. Adolf, F. Van den Berg, H. Ponta, P. Herrlich, and E. Horst. 1993. CD44 splice variants: expression during lymphocyte activation and tumor progression. Behring Inst. Mitt. 92:273-277.
10. Heider, K.H., J.W.R. Mulder, E. Ostermann, S. Susani, E. Patzelt, S.T. Pals, and G.R. Adolf. 1995. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur. J. Cancer 31A:2385-2391.
11. U.S. Food and Drug Administration. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. CBER 1-50.
12. Feyen, O., A. Lueking, A. Kowald, C. Stephan, H.E. Meyer, U. Goebel, and T. Niehues. 2008. Off-target activity of TNFalpha inhibitors characterized by protein biochips. Anal. Bioanal. Chem. 391:1713-1720.
13. Lueking, A., O. Huber, C. Wirths, K. Schulte, K.M. Stieler, U. Blume-Peytavi, A. Kowald, K. Hensel-Wiegel, et al. 2005. Profiling of alopecia areata auto-antigens based on protein microarray technology. Mol. Cell. Proteomics 4:1382-1390.
14. Tijink, B.M., J. Buter, R. de Bree, G. Giaccone, M.S. Lang, A. Staab, C.R. Leemans and G.A. van Dongen. 2006. Phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Can. Res. 12:6064-6072.
15. Angenendt, P., J. Glökler, J. Sobek, H. Lehrach, and D.J. Cahill. 2003. Next generation of protein microarray support materials: evaluation for protein and antibody microarray applications. J. Chromatogr. A 1009:97-104.